Portfolio

PORTFOLIO COMPANY SUMMARY

The RD Fund focuses on companies with late preclinical to clinical stage programs. Preclinical projects are generally within 18 to 24 months of clinical testing. The RD Fund has invested globally in multiple companies, including internally conceived startups working on a range of promising technologies and therapeutic targets, including gene therapy, RNA therapies, neuroprotection and optogenetics.

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. Atsena is developing novel gene therapies, including a Phase 1/2 clinical program for Leber congenital amaurosis (LCA1).

Status: Private
Funded by: RD Fund 1

CheckedUp is the only, physician-founded, specialty technology platform designed for the Point of Care actively engaging Patients, Caregivers, and Physicians in the Waiting Room, Exam Room, and at home. As a healthcare technology leader, CheckedUp aspires to create better educated and more confident Patients and Physicians who are empowered to make the best health decisions together.

Status: Acquired by Rockbridge
Funded by: RD Fund 1

Nacuity is a clinical stage pharmaceutical company working on a breakthrough treatment for retinitis pigmentosa (RP), addressing oxidative stress in the retina, which causes cell degeneration and vision loss in virtually all forms of RP.

Status: Private
Funded by: RD Fund 1

Nayan Therapeutics is a preclinical stage biopharmaceutical company developing mutation-agnostic therapies to treat inherited retinal diseases.

Status: Private
Funded by: RD Fund 1

Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies.

Status: Private
Funded by: RD Fund 1 and RD Fund 2

Perceive Bio is a biotechnology company developing novel therapeutics to prevent the largest causes of irreversible blindness preparing for clinic with lead programs in dry AMD & neuroprotection.

Status: Private
Funded by: RD Fund 2

ProQR is a company on a mission to create new medicines for patients in need. They focus on diseases that are very severe or life threatening and have limited treatment options such as Leber congenital amaurosis, Usher syndrome, cystic fibrosis, and dystrophic epidermolysis bullosa.

Status: Public
Funded by: RD Fund 1

SalioGen Therapeutics is focused on developing therapies for more patients with inherited diseases that are beyond what is addressable with current technologies.

Status: Private
Funded by: RD Fund 2

SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.

Status: Private
Funded by: RD Fund 1

Stargazer Pharmaceuticals is a biopharmaceutical company focused on the development of novel treatment options for rare eye diseases.

Status: Solvent dissolution
Funded by: RD Fund 1

Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss.

Vedere Bio I
Status: Acquire by Novartis
Funded by: RD Fund 1

Vedere Bio II
Status: Private
Funded by: RD Fund 1

THERAPEUTIC PIPELINE

As of June 2022